Mymetics announces new collaboration to advance the development of an innovative Malaria vaccine candidate
Epalinges, Switzerland, 18 November 2014
Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases, announced today that the PATH Malaria Vaccine Initiative (MVI) has chosen Mymetics to develop and produce virosome based vaccine formulations for a malaria transmissionblocking vaccine candidate. MVI is a global program whose objective is to accelerate the development of malaria vaccines and catalyze timely access in endemic countries.
|Media Name||Media Type||Description||Download|
|141118 Mymetics press release PATH-MVI-NIH - FINAL for release||Download|